Technologies

This innovative technology involves the use of a high-affinity, highly specific antibody that targets extracellular domains of connexin hemichannels (Cx26, Cx30, and Cx32). The antibody has been designed to reduce or inhibit the growth of brain tumors, particularly glioblastoma (GBM), and to alleviate the associated epilepsy. By blocking connexin hemichannels, the antibody interferes with pathological ATP release and other signaling mechanisms that contribute to tumor progression and neural hyperexcitability.

The development of genome editing tools has revolutionized the way we think and deal with genetics. The use of Cas9 or its variants allows modifications of specific sites in the human genome by inducing deletions and insertions in a more or less controlled way. In recent years, a new class of tools for genome editing has emerged: the base editors (BE), which result from the fusion of a modified Cas9, which serves to direct the BE to the target, and an active deaminase acting on the DNA, which mediates the C> T or A> G editing.

The technology we participate to develop, called "Zinc-Finger Artificial Transcription Factors (ZF-ATFs)", allows to design, realize and select artificial genes coding for proteins capable of recognizing and binding "potentially" any DNA sequence. We used ZF-ATF technology to reprogram the expression of "beneficial" genes capable of efficiently counteracting the negative effect of mutated genes related to rare diseases.

The present invention relates to the biomedical sector of the treatment of lung diseases and related symptoms. In particular, the present invention provides compositions and methods based on the use of selected polymeric biomaterials, in combination with stem cells and/or their secretome, capable of synergistically improving the development, regeneration and repair of chronic lung injuries and related symptoms.

Extracellular vesicles produced by teratocarcinoma cells were isolated and characterized. Functional assays on glioblastoma (GBM) cell cultures showed the inhibitory effect of these vesicles on tumor cell migration, without inducing undesirable effects such as increased cell proliferation or chemotherapy resistance.

The invention consists of a method and apparatus for the delivery at low pressure (equal to or less than 10^-7 Torr) of monoatomic fluorine for reaction with surfaces in an ultra-clean environment. Thanks to the low pressure values involved in the proposed method, the risks associated with the use of fluorine are reduced to a minimum.

The aim of the research group is the creation of 3D models (microorgan/ organoids) constructed using samples obtained from patients, both biopsy samples and samples collected with non-invasive techniques (exhaled breath condensate, induced sputum, blood samples).

An innovative approach for the treatment of diabetic and venous ulcers, characterized by a difficult healing process and therefore at potential risk of infection and therefore of hospitalization and amputation of the limb, is represented by the local administration of "bioactive" factors through the use of synthetic and/or biological matrices that allow a gradual and controlled release in order to obtain a better and faster healing.

Recently, nanoparticles and nanovesicles have been investigated as potential approaches for the treatment of neurodegenerative diseases. In particular, in the Biotech sector an increasingly deeper penetration of new treatment models and biological drugs based on cellular, subcellular and vesicle therapies is expected. The patent is based on the production of Myelin-based nanoVesicles (MyVes) produced by microfluidics, starting from myelin extracted from brain tissue. These vesicles find two major fields of applications as potential drugs or as supplements/nutraceuticals.

The development of new materials with near-infrared emission (NIR, 700 – 1000 nm) represent an important target in the technological progress of innovative active components for OLED devices (including flexible ones), surveillance systems, autonomous driving, night vision sensors, fiber optic telecommunications and medical systems. In all these fields it still lacks a commercial NIR-OLED technology.

Therapeutic strategies targeting cell cycle in cancer have in general failed in the clinic since the drugs have lacked the therapeutic index required to achieve a robust response against cancer cells with little or no cytotoxic effect on normal cells. NEK6 kinase, which is implicated in cell cycle control, has recently emerged as an attractive target for the development of novel anticancer drugs with enhanced therapeutic index.

With the advent of senolytic agents, capable of selectively removing senescent cells in “aged” tissues, the perception of age-associated diseases has changed from being an inevitable to a preventable phenomenon of human life. The present invention is part of this research topic with the identification of molecules with potential pro-apoptotic activity, specifically with senolytic activity. The computational approach adopted, is based on combining ligand-base and structure-based virtual screening.

Celiac disease and non-celiac gluten sensitivity affect a large portion of the world population. Furthermore, the percentage of people who adopt the gluten free diet is constantly increasing because it is perceived to be healthier. We have previously developed a food grade enzymatic procedure (transamidation) for wheat flour capable of making gluten unable to induce the inflammatory response in the intestine of celiac disease patients.

Currently, liposomes (artificially synthesised vesicles) are widely used as carriers for a variety of molecules in the cosmetic and pharmaceutical industries. In the clinical applications, for instance, they are employed to encapsulate a range of substances, such as antibiotics, proteins, genetic material, vitamins and anti-cancer drugs.

The technology refers to an innovative plasma (ionized gas) source operating at atmospheric pressure and low electric power levels. A cold plasma is produced, characterized by an ion temperature significantly lower than the electron temperature. Partial ionization of a Helium flux is induced by a time-varying electric field in between two parallel grids, both perpendicular to the flux itself.